Health
GSK says long-acting HIV prevention drug 66% more effective than Truvada – WHTC News
(Reuters) – Britain’s GSK said on Tuesday that an injection of its cabotegravir drug given every two months was found to be 66% more effective in preventing HIV infections than Gilead’s Truvada daily oral pills.
HIV incidence rate – or the number of people wh…
(Reuters) – Britain’s GSK said on Tuesday that an injection of its cabotegravir drug given every two months was found to be 66% more effective in preventing HIV infections than Gilead’s Truvada daily…
Continue Reading